使用Player FM应用程序离线!
INTERLACE Study Boosts Cervical Cancer Survival
Manage episode 403707763 series 1021077
A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy.
At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, reported findings from the GCIG INTERLACE randomized Phase III trial of induction chemotherapy. This involved the use of carboplatin with paclitaxel for 6 weeks immediately before standard chemoradiotherapy.
After the conference, OncTimesTalk’s correspondent Peter Goodwin visited McCormack to find out more about the clinical implications arising from the INTERLACE study.
145集单集
Manage episode 403707763 series 1021077
A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy.
At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, reported findings from the GCIG INTERLACE randomized Phase III trial of induction chemotherapy. This involved the use of carboplatin with paclitaxel for 6 weeks immediately before standard chemoradiotherapy.
After the conference, OncTimesTalk’s correspondent Peter Goodwin visited McCormack to find out more about the clinical implications arising from the INTERLACE study.
145集单集
所有剧集
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。